Effects of the combined artesunate and mefloquine antimalarial drugs on rat embryos

10Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

Artemisinins combination therapy (ACT) is the first choice therapy for falciparum malaria. Data on the safety of ACTs in pregnancy are limited and controversial and the use is not recommended on the first trimester. To evaluate the effects of isolated and combined artesunate (AS)/mefloquine (MQ) on embryo rats, pregnant rats were treated orally with AS (15 and 40 mg/kg body weight (bwt)/day), MQ (30 and 80 mg/kg bwt/day) and AS/MQ (15/30 and 40/80 mg/kg bwt/day) on days 9-11 post coitum (pc). The dams were euthanized on day 12 pc and gestational and embryos histological parameters were evaluated. Embryolethality and histopathological anomalies were significant when AS was given alone or combined with MQ. Combination of AS and MQ did not enhance their toxicity compared to their separate administrations; on the other side, there was a reduction in the toxic effects of the AS when combined with MQ. Isolated MQ did not induce developmental toxicity. © The Author(s) 2013.

Cite

CITATION STYLE

APA

Boareto, A. C., Müller, J. C., Lourenço, E. L. B., Lombardi, N., Lourenço, A. C., Rabitto, I., … Dalsenter, P. R. (2013). Effects of the combined artesunate and mefloquine antimalarial drugs on rat embryos. Human and Experimental Toxicology, 32(9), 930–941. https://doi.org/10.1177/0960327113475678

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free